Century Therapeutics, Inc

Today, we reported financial results and business highlights for Q2 2024. Read the full press release: https://bit.ly/4fy0cBv #biotech #investors

In celebration of #NationalInternDay, we would like to give a shoutout to our talented interns at Century who have been an essential part of our team this summer. Thank you for your hard work, dedication and passion to supporting our mission to develop iPSC-derived #celltherapies for the treatment of #cancer and #autoimmune and #inflammatory diseases. #Interns #STEM

We recently hosted a Century Charity Golf Invitational, raising over $1000 for The Leukemia & Lymphoma Society! Thank you to our incredible team for supporting this organization’s important work to create a world without #bloodcancers. #cancerresearch #cancelbloodcancer #giveback

This Sunday is #NationalIceCreamDay! To celebrate, we hosted ice cream parties for team members at all our office locations. Check out the photos to get a glimpse of these sweet events.  

We look forward to participating in the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 10. We're excited to reconnect with the #biotech community and discuss our ongoing work to address significant unmet needs for patients with #autoimmune and #inflammatorydiseases. #iPSC #celltherapy

This past week, team members participated in group spin classes to celebrate #EmployeeHealthAndWellnessMonth. We enjoy organizing events like these that support our colleagues’ well-being and provide a fun opportunity to recharge and connect with each other. 

June is #NationalCancerSurvivorsMonth. At Century, we honor the courage and resilience of all cancer survivors and remain committed to expanding patient access to life-saving cell therapies so that one day all patients with cancer can become survivors. #CelebrateSurvivorship #CancerResearch

Today, we announced a poster presentation at the American Society of Clinical Oncology (ASCO)) annual meeting highlighting interim results from the ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) #lymphoma. The poster showcases CNTY-101’s continued encouraging preliminary efficacy and manageable safety profile for with no observed DLTs or GvHD. Learn more: https://bit.ly/3RaEI3k #ASCO2024

We are looking forward to the American Society of Clinical Oncology (ASCO) Annual Meeting, where we will present interim data from our ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) non-Hodgkin #lymphoma. We hope to see you at #ASCO24!

Century recognizes #LupusAwarenessMonth as part of the community dedicated to supporting those with Systemic Lupus Erythematosus. Recently, we hosted a booth at the LuCIN Community Meeting to further educate on the potential of CNTY-101 in #SLE and our planned CALiPSO-1 trial.